ADP receptors on platelets and ADP-selective antiaggregating agents

Medicinal Research Reviews

Volumn 16, Issue 2, 1996, Pages 159-179

  Savi, Pierre ^a   Herbert, Jean Marc ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE RECEPTOR; ANTITHROMBOCYTIC AGENT; CALCIUM; CLOPIDOGREL; DIPYRIDAMOLE; INOSITOL PHOSPHATE; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; BRAIN HEMORRHAGE; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; HUMAN; METABOLIC ACTIVATION; NONHUMAN; PERIPHERAL VASCULAR DISEASE; REVIEW; SECOND MESSENGER; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE SHAPE;

EID: 0029875777     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-1128(199603)16:2<159::aid-med2>3.0.co;2-%23     Document Type: Review

References (207)

1. Anti-platelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy, Br. Med. J., 296, 320-331 (1988).
2. A. Castaigne, A. M. Duval-Moulin, and C. Dutroit, Antiagregants plaquettaires et et pathologie coronaire. Rev. Prat., 39, 2228-2233 (1989).
3. R. Limct, J. L. David, and P. Magotteaux, Prevention of aorta coronary bypass graft occlusion, J. Thorac Cardiovasc. Surg., 94, 774-783 (1987).
4. D. Adams and M. G. Bousser, Antiagregants plaquettaires en pathologie ischemique cerebrale, Rev. Prat., 39, 2234-2240 (1989).
5. W K. Hass, J. D. Easton, H. P. Adams, Jr., W. Pryse-Philhps, B. A. Molony, S. Anderson, and B. Kamm, writers for the Ticlopidine Aspirin Stroke Study (TASS). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients, N. Engl. J. Med., 321, 501-507 (1989).
6. M. Gent, J. D. Easton, V. C. Hachinski, E. Panak, J. Sicurella, J. A. Blakely, D. J. Ellis, J. W. Harbison, R. S. Roberts, and A. G. G. Turpie, writers for the Canadian American Ticlopidine Study (CATS). The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke, Lancet, June 3, 1215-1220 (1989).
7. J. P. Boissel, J. C. Peyrieux, and J. M. Destors, Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?, Thromb. Haemost., 62, 681-685 (1989).
8. J. M. Herbert, D. Frehel, E. Vallee, G Kieffer, D. Gouy, Y. Berger, J. Necciari, G. Defreyn, and J. P. Maffrand, Clopidogrel, A novel antiplatelet and antithrombotic agent, Cardiovasc. Drug Res., 11, 180-198 (1993).
9. K. Schror, The basic pharmacology of ticlopidine and clopidogrel, Platelets, 4, 252-261 (1993).
10. H. Lee, R. C. Paton, C. Ruan, and J. P. Caen, The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets, Thromb. Haemostas., 46, 590-592 (1981).
11. R. Le Menn, Ultrastruture of blood platelet aggregation. Effect of an inhibitor: Ticlopidine, Biol. Cell, 43, 179-188 (1982).
12. J. P. Maffrand, G. Defreyn, A. Bernat, D. Delebassee, and A. M. Tissinier, Reviewed pharmacology of ticlopidine, Act. Med. Int., 77, 6-13 (1988).
13. C. Picard-Fraire, Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function, Agents Action, 15, 68-75 (1984).
14. T. Di Perri, F. L. Pasini, C. Frigerio, P. Blardi, F. Centini, G. L. Messa, A. Ghezzi, and L. Volpi, Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration, Eur. J. Clin. Pharmacol., 41, 429-434 (1991).
15. E Panak, J. P. Maffrand, C. Picard-Fraire, E. Vallee, J. Blanchard, and R. Roncucci, Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications, Haemostasis, 13, suppl. 1, 1-54 (1983).
16. P. Savi, E. Heilmann, P. Nurden, M. Cl. Laplace, C. Bihour, G. Kieffer, A. T. Nurden, and J. M. Herbert, Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin. Appl. Thrombosis/Hemostasis (in press).
17. M. C. Gambino, S. Passaghe, Z. M. Chen, F. Bucchi, G. Gori, R. Latini, G. De Gaetano, and C. Cerletti, Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyclooxygenase activity is reduced by portacaval shunt in rats, J. Pharmacol. Exp. Ther , 245, 287-290 (1988).
18. P. Savi, J. M. Herbert, A. M. Pflieger, F. Dol, D Delebassee, J. Combalbert, G. Defreyn, and J. P. Maffrand, Importance of hepatic metabolism for the anti-aggregating activity of the thienopyridine clopidogrel, Biochem. Pharmacol., 44(3), 527-532 (1992).
19. P. Savi, J. Combalbert, C. Gaich, M -C. L. Rouchon, J. P. Maffrand, Y. Berger, and J. M. Herbert, The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450 1A, Thromb. Haemost., 72(2), 313-317 (1994).
20. C. B. Harbury and S. L. Schrier, Modification of platelet sulfhydryl groups, Thrombos. Diath. Haemorrh., 31, 469-484 (1974).
21. D. E. Maclntyre, C. A. Grainge, A. H. Drummond, and J. L. Gordon, Effects of thio reagents on platelet transport processes and responses to stimuli, Btochem. Pharmacol., 26, 319-323 (1977).
22. L. M. Aledort, S. B. Troup, and R. I. Weed, Inhibition of sulfhydryl-dependent platelet function by penetrating and non penetrating analogues of parachloromercuribenzene, Blood, 31, 471-479 (1968).
23. M. B. Zucker and E. A. Mauss, Modification of platelet functions by monobromobimane, a fluorescent thiol group label, Thromb. Haemostas., 55, 228-234 (1986).
24. W. A. Groenewegen and S. Heptinstall, A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in vitro, J. Pharm. Pharmacol., 42, 553-557 (1990).
25. H. Patscheke and P. Worner, Sequential effects of the thiol-oxidizing agent, diamide, on human platelets, Thromb. Res., 12, 609-618 (1978).
26. A. Bosia, P. Spangenberg, W. Losche, P. Arese, and U. Till, The role of the GSH-disulfide status in the reversible and irreversible aggregation of human platelets, Thromb. Res., 30, 137-142 (1983).
27. E Dejana, B. Barbieri, C. Cerletti, M. Livio, and G. De Gaetano, Impaired thromboxane production by newly formed platelets after aspirin administration to thrombocytopenic rats, Br. J. Haematol., 46, 465-469 (1980).
28. A. Bernat, E. Vallee, J. P. Maffrand, and R. Roncucci, Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis, Thromb. Res., 37, 279-285 (1985).
29. J. P. Maffrand, A. Bernat, D. Delebassee, G. Defreyn, J. P. Cazenave, and J. L. Gordon, ADP plays a key role in thrombogenesis in rats, Thromb. Haemostas , 59, 225-230 (1988b).
30. D. McTavish, D. Faulds, and K. L. Goa, Ticlopidine: an update review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs, 40, 238-259 (1990).
31. A. Bernat, A. M. Mares, G. Defreyn, J. P. Maffrand, and J. M. Herbert, Effect of various antiplatelet agents on acute arterial thrombosis in the rat, Thromb. Haemostasis, 70, 812-816 (1993).
32. A. Bernat, E. Vallee, J. P. Maffrand, and J. L. Gordon, The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat, Thromb. Res , 52, 65-70 (1988).
33. J. M. Herbert, A. Bernat, and J. P. Maffrand, Importance of platelets in experimental venous thrombosis in the rat, Blood, 80, 2281-2286 (1992).
34. A. Szczeklik, M. Krzanowski, P. Gora, and J. Radwan, Antiplatelet drugs and generation of thrombin in clotting blood, Blood, 80, 2006-2011 (1992).
35. A. Bernat, F. Dol, J. M. Herbert, M. Sainte-Marie, and J. P. Maffrand, Potentiating effects of anticoagulants and antiplatelet agents on streptokinase-induced thrombolysis in the rabbit, Fibrinolysts, 7, 23-30 (1993)
36. L. I. Valentin, G. A. Sicard, M. B. Freeman, B. T. Allen, and M. A. McGoff, Combined arachidonic acid and ADP platelet inhibition maximises patency of small-diameter vascular grafts, Surgery (St. Louis), 104, 178-184 (1988).
37. F. W. Dunn, J. Soria, C. Soria, A. Thomaidis, H. Lee, and J. P. Caen, In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets, Agents Action Suppl., 15, 97-104 (1984).
38. C. Gachet, A. Stierle, J. P. Cazenave, P. Ohlmann, F. Lanza, C. Bouloux, and J. P Maffrand, The thienopyridine PCR 4099 selectively inhibits ADP-mduced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man, Biochem. Pharmacol , 40, 229-238 (1990).
39. R. Feliste, D. Delebassee, M. F. Simon, H. Chap, G. Defreyn, E. Vallee, L. Douste-Blazy, and J. P. Maffrand, Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP, Thromb. Res., 48, 403-415 (1987).
40. M. Chignard, C. Lalau Keraly, D. Delautier, C. Sebag, C. Bouloux, G. Motte, and J. Benveniste, Reduced sensitivity of human platelets to PAF-acether following ticlopidine intake, Haemosiasis, 19, 213-218 (1989).
41. J. L. David, F. Monfort, F. Herion, and R. Raskinet, Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects, Thromb. Res., 14, 35-49 (1979)
42. C. Cimminiello, M. Milani, T. Uberti, G. Arpaia, and G. Bonfardeci, Effects of ticlopidine and indobufen on platelet aggregation induced by A23187 and adrenaline in the presence of different anticoagulants, J. Int. Med. Res , 17, 514-520 (1989).
43. M. Cattaneo, B. Akkawat, R. L. Kinlough-Rathbone, M. A. Packham, C. Cimminiello, and P. M. Mannucci, Ticlopidine facilitates the deaggregation of human platelet aggregated by thrombin, Thromb. Haemostasis, 71, 91-94 (1994).
44. C. Gachet, and J. P. Cazenave, ADP receptor: A review, Nouv. Rev. Fre. Hématol., 33, 347-358 (1992).
45. E. W. Salzman, D. A. Chambers, and L. L. Neri, Possible mechanism of aggregation of blood platelets by adenosine diphosphate, Nature (Lond.), 210, 167-169 (1966).
46. D. C. B. Mills, Changes in the adenylate energy charge in human blood platelets induced by adenosine diphosphate, Nature Neture Biology, 243, 220-222 (1973).
47. M. A. Packham, M. A. Guccione, D. W. Perry, and J. F. Mustard, Interactions of nucleotide di and triphosphates with rabbit platelets, Am. J. Physiol., 227, 1143-1148 (1974).
48. D. C. B. Mills and C. Lipson, Is phosphorylation of ADP required for the induction of shape change and aggregation?, Thromb. Haemostas., 46, 195 (post 610) (1981).
49. G. V. R. Born, D Bergquist, and K. E. Arfors, Evidence for inhibition of platelet activation in blood by a drug effect on erythrocytes, Nature (Lond.), 259, 233-235 (1976).
50. A. Gaarder, J. Jonsen, S. Laland, A. Hellem, and P. A. Owren, Adenosine diphosphate in red cells is a factor in the adhesiveness of human blood platelets. Nature (Lond.), 192, 531-532 (1961).
51. G. V. R. Born, Adenosine diphosphate as a mediator of platelet aggregation in vivo: An editorial view, Circulation, 72, 741-746 (1985).
52. M. Cattaneo, M. T. Canciani, A. Lecchi, R. L. Kinlough-Rathbone, M. A. Packham, P. M. Mannucci, and J. F. Mustard, Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates, Blood, 75, 1081-1086 (1990).
53. W. R. Wagner, and J. A. Hubbell, ADP receptor antagonists and converting enzyme systems reduce platelet deposition onto collagen, Thromb. Haemostas , 67, 461-467 (1992).
54. K. M. Zawilska, G. V. R. Born, and N A. Begent,. Effects of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits, Br. J. Haematol , 50, 317-325 (1982).
55. J. R. O'Brien and J. B. Heywood, Effect of aggregating agents and their inhibitors on the mean platelet shape, J. Clin. Path., 19, 148-153 (1966).
56. G. V. R. Born, Observations on the change in shape of blood platelets brought about by adenosine diphosphate, J. Physiol., 209, 487-511 (1970).
57. D. A. Deranleau, D. Dubler, C. Rothen, and E. F. Lüscher, Transient kinetics of the rapide shape change of unstirred human blood platelets stimulated by ADP, Proc. Natl. Acad. Sci. USA, 79, 7297-7301 (1982).
58. J. G. White, Fine structural alterations induced in platelets by adenosine diphosphate, Blood, 31, 604-622 (1968).
59. J. G. White, "The morphology of platelet function," in L. A. Harker and T. S. Zimmerman, Eds., Measurements of Platelet Functcion, Churchill Livingstone, Edinburgh, 1983, pp. 1-25.
60. L. G. Pedvis, T. Wong, and M. M. Frojmovic, Differential inhibition of the platelet activation sequence: Shape change, micro- and macro-aggregation, by a stable prostacyclin analog (iloprost), Thromb. Haemostas., 59, 323-328 (1988).
61. P. Savi, M. C. Laplace, and J M. Herbert, Evidence for the existence of two different ADP-binding sites on rat platelets, Thromb. Res , 76(2), 157-169 (1994).
62. J. L. Daniel, I. R. Molish, M. Rigmaiden, and G. Stewart, Evidence for a role of myosin phosphorylation in the initiation of the platelet shape change response, J. Biol. Chem., 259, 9826-9831 (1984).
63. J. E B Fox and D. R. Phillips, Inhibition of actin polymerization in blood platelets by cytochalasins, Nature (Lond.), 292, 650-652 (1981).
64. E I. Peerschke and M. B. Zucker, Relationship of ADP-induced fibrinogen binding to platelet shape change and aggregation elucidated by use of colchicine and cytochalasin B, Thrombo. Haemostas., 43, 58-60 (1980).
65. R. Feliste, M. F. Simon, H. Chap, L. Douste-Blazy, G. Defreyn, and J. P. Maffrand, Effects of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat platelets, Biochem. Pharmacol., 37, 2559-2564 (1988).
66. G. V. R. Born, Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Land.), 194, 927-929 (1962).
67. M. H. Kroll and A. I. Schafer, Biochemical mechanisms of platelet activation, Blood, 74, 1181-1195 (1989).
68. W. Siess, Molecular mechanisms of platelet activation, Physiol. Rev., 69, 58-178 (1989).
69. M. Cattaneo, B. Akkawat, A Lecchi, C. Cimminiello, A. M. Capitanio, and P. M. Mannucci, Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate, Thromb Haemostasis, 66, 694-699 (1991).
70. C. Gachet, P. Savi, P. Ohlmann, J. P. Maffrand, K. H. Jakobs, and J P Cazenave, ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes - An effect selectively blocked by the thienopyridine clopidogrel, Thromb. Haemostas., 68, 79-83 (1992).
71. J. M. Herbert, D. Frehel, A. Bernat, A. Badorc, P. Savi, D. Delebassee, G. Kieffer, G. Defreyn, and J. P. Maffrand, Clopidogrel hydrogenosulfate, Drugs Future, 18, 107-112 (1993).
72. P. Savi, F. Dol, and J. M. Herbert, ADP-dependence of platelet activation induced by a thrombin receptor agonist, Nouv. Rev. Fr. Hematol., 35, 115-119 (1993).
73. J. F. Mustard and M. A. Packham, Factors influencing platelet function: Adhesion, release, and aggregation, Pharmacol. Rev., 22, 98-187 (1970).
74. S. Niewiarowski and J. C. Holt, "Platelet a-granule proteins. Biochemical and pathological aspects," in The Platelets: Physiology and Pharmacology, G. L. Longenecker, Ed., Academic Press, Orlando, 1985, pp. 49-83.
75. J. F. Mustard, D. W. Perry, R. L. Kinlough-Rathbone, and M. A. Packham, Factors responsible for ADP-induced release reactions of human platelets, Am. J. Physiol., 228, 1757-1765 (1975).
76. B. Lages and H. Weiss, Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents, Thromb. Haemostas., 45, 173-179 (1981).
77. 2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents, Thromb. Haemostas., 62, 968-976 (1989).
78. M. B. Zucker, and J. Peterson, Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion, Proc. Soc. Exp. Biol. Med , 127, 547-551 (1968).
79. J. B. Knudsen and J. Gormsen, The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro, Thromb. Res., 16, 663-671 (1979).
80. J. D. Wencel-Drake and H. Feinberg, ADP induced depolarization of human platelet membrane potential, Thromb. Haemostas., 53, 75-79 (1985).
81. 2+ mobilization in human platelets stimulated by ADP and the thromboxane mimetic U 46619, J. Biol. Chem., 264, 719-725 (1990).
82. A. Ogawa, Y. Ishikawa, and S. Sasakawa, Effects of changes in intracellular pH induced by platelet storage and treatment with monovalent cation ionophores on platelet functions, Thromb. Res., 52, 369-379 (1988).
83. 2+ mobilization start simultaneously in thrombin-stimulated platelets, Biochem. J., 258, 521-527 (1989).
84. + exchange as a modulator of platelet activation. Trends Biochem, Sci., 13, 148-151 (1988).
85. + exchange and aggregation of human platelets activated by ADP: The exchange is not required for aggregation, Biochim. Biophys. Acta, 938, 425-433 (1988).
86. C. K. Derian, R. J. Gould, and P. A. Friedman, Proaggregatory effect of epinephrine on rabbit platelets inhibited by ticlopidine, Thromb. Res , 57, 393-403 (1990).
87. D. H. Haynes, Effects of cyclic nucleotides and protein kinases on platelet calcium homeostasis and mobilization, Platelets, 4, 231-242 (1993).
88. A. H. Drummond, and D. E. Macintyre, "Platelet inositol lipid metabolism and calcium flux," in Platelets in Biology and Pathology III, D. E. Maclntyre and J. L. Gordon, Eds., Elsevier, Amsterdam, 1987, pp. 373-431.
89. T J. Hallam and T. J. Rink, Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator Quin2, J. Physiol., 368, 131-146 (1985).
90. M. P. Mahaut-Smith, S. O. Sage, and T. J. Rink, Receptor-activated single channels in intact human platelets, J. Biol. Chem., 265, 10479-10483 (1990).
91. 2+, Biochem. J., 258, 923-926 (1989).
92. M. E. Rybak, L. A. Renzulli, M J. Bruns, and D. P. Cahaly, Platelet glycoprotein IIb and IIIa as a calcium channel in liposomes, Blood, 72, 714-720 (1988).
93. T. Fujimoto, K. Fujimura, and A. Kuramoto, Electrophysiological evidence that glycoprotein IIb-IIIa complex is involved in calcium channel activation on human platelet plasma membrane, J Biol Chem., 266, 16370-16375 (1991).
94. 2+] in aequorin-loaded human platelets. Platelets, 4, 201-206 (1993).
95. T. Lecompte, F. Potevin, P. Champeix, M C. Morel, R. Favier, M F. Hurtaud, N. Schlegel, M. Samama, and C. Kaplan, Aequorin-detected calcium changes in stimulated thrombasthenic platelets. Aggregation-dependent calcium movement in responses to ADP, Thromb. Res., 58, 561-570 (1990).
96. S. O. Sage and T. J. Rink, Kinetic differences between thrombin-induced and ADP-induced calcium influx and release from internal stores in fura-2-loaded human platelets, Biochem. Biophys. Res. Commun., 136, 1124-1129 (1986).
97. F. O'Rourke and M. B. Feinstem, The inositol 1,4,5-trisphosphate receptor binding sites of platelet membranes. pH-dependency, inhibition by proteolytic sulphates, and the possible presence of arginine at the binding site, Biochem J., 267, 297-302 (1990).
98. 2+ in platelets is controled by cyclic AMP: Antagonism between stimulators and inhibitors of adenylate cyclase, Biochem. Biophys. Res. Commun., 120, 579-585 (1984).
99. R. O. Morgan and A. C. Newby, Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets, Biochem. J., 258, 447-454 (1989).
100. M. B. Feinstein, G. B. Zavoico, and S. P. Halenda, "Calcium and cyclic AMP. Antagonistic modulators of platelet function," in The Platelets: Physiology and Pharmacology, G L. Longenecker, Ed., Academic Press, Orlando, 1985, pp. 237-269
101. J. M. Gerrard, R C, Carroll, S. J. Israels, and L. L. Beattie, "Protein phosphorylation, in Platelets in Biology and Pathology III, D E. Maclntyre and J. L. Gordon, Eds, Elsevier, Amsterdam, 1987, pp. 317-351.
102. J. L. Daniel, C. A. Dangelmaier, M. Selak, and J. B. Smith, ADP stimulates IP3 formation in human platelets, FEBS Lett., 206, 299-303 (1986).
103. H. P. Jones, "Calmodulin and platelet function," in The Platelets: Physiology and Pharmacology, G. L. Longenecker, Ed., Academic Press, Orlando, 1985, pp. 221-235.
104. J. B. Moore, B. L. Fuller, R. Falotico, and E L, Tolman, Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers, Thromb. Res., 40, 401-411 (1985).
105. M. Schachter, Do calcium antagonists affect platelets?, Eur. Heart J , 8 (Supp. K), 75-82 (1987).
106. J. A. Ware, P. C. Johnson, M. Smith, and E. W. Salzman, Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: Studies with aequorin and quin2, Cir. Res., 59, 39-42 (1986).
107. 2T-purinoreceptors on human blood platelets, Br. J. Pharmacol., 108, 728-733 (1993).
108. 2+ thresholds and Ca-independent activation for shape-change and secretion, FEBS Lett., 148, 21-26 (1982).
109. R. M. Hardisty, M. J. Powling, and T. J. C Nokes, The action of ticlopidine on human platelets. Studies of aggregation, secretion, calcium mobilization and membrane glycoproteins, Thromb. Haemostas., 64, 150-155 (1990).
110. C. Gachet, J. P. Cazenave, P. Ohlmann, C. Bouloux, G. Defreyn, F. Driot, and J. P. Maffrand, The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1, Biochem. Pharmacol., 40, 2683-2687 (1990).
111. 2+ mobilisation in rat platelets, Res. Commun. Chem. Pathol. Pharmacol., 54, 275-278 (1986).
112. C. K. Derian and P. A. Friedman, Effects of ticlopidine ex vivo on platelet intracelluar calcium mobilization, Thromb. Res. 50, 65-76 (1988).
113. H. Chap, B. Perret, M. Plantavid, H. Lachachi, and L. Douste-Blazy, "Topography of platelet membrane phospholipids," in Platelets in Biology and Pathology, Maclntire and Gordon, Eds., Elsevier Science Publishers B.V., Amsterdam, New York, Oxford, 1987, pp. 191-204.
114. 2+, phospholipid-dependent protein kinase associated with plasma membrane, Nature (Lond.), 301, 621-623 (1983).
115. 2+, phorbol esters, and ATP, J. Biol. Chem., 260, 15718-15722 (1985).
116. R. J. Haslam, H. B. Koide, and B. A. Hemmings, Pleckstrin domain homology, Nature (Lond.), 363, 309-310 (1993).
117. J. M. Gerrard, L. L. Beattie, J. Pari, S. J. Israels, A McNicol, D. Lint, and E. J. Cragoe, Jr., A role for protein kinase C in the membrane fusion necessary for platelet granule secretion, Blood, 74, 2405-2413 (1989).
118. J. D. Vickers, R. L. Kinlough-Rathbone, M. A. Packham, and J. F. Mustard, Inositol phospholipid metabolism in human platelets stimulated by ADP, Eur. J. Biochem., 193, 521-528 (1990).
119. M. A. Packham, A. A. Livne, D. H. Ruben, and M. L. Rand, Activation of phospholipase C and protein kinase C has little involvement in ADP-induced primary aggregation of human platelets: Effects of diacyglycerols, the diacylglycerol kinase inhibitor R59022, staurosporine and okadaic acid, Biochem. J., 290, 849-856 (1993).
120. S. Raha, G. D Jones, and A. R. L. Gear, Sub-second oscillations of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate during platelet activation by ADP and thrombin: Lack of correlation with calcium kinetics, Biochem. J., 292, 643-646 (1993).
121. H. S. Banga, E. R. Simons, L. F. Brass, and S. E. Rittenhouse, Activation of phospholipase A2 and C in human platelets exposed to epinephrine: Role of glycoproteins IIb/IIIa and dual role of epinephrine, Proc. Natl. Acad. Sci. USA, 83, 9197-9201 (1986).
122. 3 integrin) in thrombin-induced synthesis of phosphatidylinositol 3′,4′-bisphosphate, J. Biol. Chem., 266, 23554-23557 (1991).
123. G. Di Minno, A. M. Cerbone, P. L. Mattioli, S. Turco, C. Iovine, and M. Mancini, Functionally thrombasthenic state in normal platelets following the administration of ticlopidine, J. Clin. Invest., 75, 328-338 (1985).
124. S. Rotondo, E. Tascione, C. Cerletti, and G. De Gaetano, Ticlopidine does not reduce in vivo platelets thromboxane biosynthesis and metabolism in diabetic patients, Platelets, 4, 97-100 (1993).
125. A. Spreca, M. G. Rambotti, and R. Donato, Particulate guanylate cyclase and adenylate cyclase activities after activation with various agents in rabbit platelets An ultracytochemical study, Histochem. J., 23, 143-148 (1991).
126. B. T. Mellion, L. J. Ignarro, E. H. Ohlstein, E. G. Pontecorvo, A. L. Hyman, and P. J. Kadowitz, Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators, Blood, 57, 946-955 (1981).
127. Y. Y. Chirkov, J. I. Naujalis, S. Berber, R. E. Sage, D. W. Gove, J. K Brealey, and J. D. Horowitz, Reversal of human platelet aggregation by low concentration of nitroglycerin in vitro in normal subjects, Cardiovasc. Pharmacol., 70, 802-806 (1992).
128. Y. Y. Chirkov, N. N. Belushkina, I. A. Tyshchuk, I. S. Severina, and J. D. Horowitz, Increase in reactivity of human platelet guanylate cyclase during aggregation potentiates the disaggregating capacity of sodium nitroprusside, Clin. Exp Pharmacol. Physiol., 18, 517-524 (1991).
129. M. W. Radomski, R. M. J. Palmer, and S. Moncada, An L-arginine/nitric oxide pathway present in human platelets regulates aggregation, Proc. Nat. Acad. Sci. USA, 87, 5193-5197 (1990).
130. I. S. Severina, Soluble guanylate cyclase of platelets: Function and regulation in normal and pathological states, Adv. Enzyme Regul., 32, 35-56 (1992).
131. R. Waldmann, S. Bauer, C. Göbel, F. Hofmann, K. H. Jakobs, and U. Walter, Demonstration of cGMP-dependent protein kinase and cGMP-dependent phosphorylation in cell-free extracts of platelets, Eur. J Biochem., 158, 203-210 (1986).
132. M F. Simon, and H. Chap, Inhibition of calcium influx in thrombin-stimulated platelets by SIN-1, an activator of soluble guanylate cyclase, J. Cardiovasc. Pharmacol., 14 (Suppl. 11), S106-S110 (1989).
133. D. Ghigo, R. Heller, R. Calvino, P. Alessio, R. Fruttero, A. Gasco, A. Bosia, and G. Pescarmona, Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets, Biochem. Pharmacol , 43, 1281-1288 (1992).
134. R. J. Haslam, Interactions of the pharmacological receptors of blood platelets with adenylate cyclase, Ser. Haemat., 6, 333-350 (1973).
135. R. J. Haslam and G. M. Rosson, Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation, Mol. Pharmacol., 11, 528-544 (1975).
136. B. Ashby, Cyclic AMP turnover in response to prostaglandins in intact platelets: Evidence for separate stimulatory and inhibitory prostaglandin receptors, Second Messengers Phosphoproteins, 12, 45-57 (1988).
137. K. H. Jakobs, W. Saur, and G. Schultz, Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine, J. Cyclic Nucleotide Res., 2, 381-392 (1976).
138. K. Aktories and K. H. Jakobs, Ni-mediated inhibition of human platelet adenylate cyclase by thrombin, Eur. J. Biochem., 145, 333-338 (1984).
139. K. P. Mellwig and K. H. Jacobs, Inhibition of platelet adenylate cyclase by ADP, Thromb. Res., 18, 7-17 (1980).
140. D. M. F. Cooper and M. Rodbell, ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase, Nature (Lond.), 282, 517-518 (1979).
141. C. Gachet, J. P. Cazenave, P Ohlmann, G. Hilf, T Wieland, and K. H. Jakobs, ADP receptor-induced activation of guanine nucleotide binding proteins in human platelet membranes, Eur. J. Biochem., 207, 259-263 (1992).
142. 2 purinoreceptors with unique properties modulates the function of human platelets, Biochim. Biophys. Acta, 1177, 199-207 (1993).
143. E. G. Lapetina, J. C. Lacal, B. R. Reep, Y. Molina, and L. Vedia, A ras-related protein is phosphorylated and translocated by agonists that increase cAMP levels in human platelets, Proc. Natl. Acad. Sci. USA, 86, 3131-3134 (1989).
144. S. Berry, D. D. Dawicki, and M. Steiner, Time resolved analysis of tubulin phosphorylation during platelet activation, Biochem. Biophys. Res. Commun., 159, 170-176 (1989).
145. J. E. B. Fox and M. C. Brendt, Cyclic AMP-dependent phosphorylation of glycoprotein Ib inhibits collagen-induced polymerization of actin in platelets, J. Biol. Chem., 264, 9520-9526 (1989).
146. G. Van Willigen and J. W. N. Akkerman, Protein kinase C and cyclic AMP regulate reversible exposure of binding sites for fibrinogen on the glycoprotein IIb-IIIa complex of human platelets, Biochem. J., 273, 115-120 (1991).
147. D. E. MacFarlane and D. C. B Mills, Inhibition by ADP of prostacyclin induced accumulation of cyclic AMP in intact human platelets, J. Cyclic Nucleotide Res., 7, 1-11 (1981).
148. 32P]diphosphate, an agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets, J Clin. Invest., 71, 420-428 (1983).
149. 32P]-diphosphate to the receptor on intact human blood platelets which inhibits adenylate cyclase, Biochemistry, 21, 544-549 (1982).
150. N. J. Cusack, S. M. O. Hourani, Competitive inhibition by adenosine 5′-triphosphate of the actions on human platelets of 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-methylthioadenosine 5′-diphosphate, Br. J. Pharmacol , 77, 329-333 (1982).
151. G. Cristalli and D. C. B. Mills, Identification of a receptor for ADP on blood platelets by photoaffinity labelling, Biochem. J , 291, 875-881 (1993).
152. N. J. Cusack and S. M. O. Hourani, Partial agonist behaviour of adenosine 5′-O-(2-thiodiphosphate) on human platelets, Br. J. Pharmacol., 73, 405-408 (1981).
153. N. J. Cusack and S. M. O Hourani, Effects of Rp and Sp diastereoisomers of adenosine 5′-O-(1-thiodiphosphate) on human platelets, Br. J. Pharmacol., 73, 409-412 (1981).
154. N. J. Cusack and S. M. O. Hourani, Adenosine 5′-diphosphate antagonists and human platelets: No evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors, Br. J. Pharmacol., 76, 221-227 (1982).
155. N. J. Cusack and S. M. O. Hourani, Competitive inhibition of adenosine 5′-triphosphate of the actions on human platelets of 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-methylthioadenosine 5′-diphosphate, Br J. Pharmacol., 77, 329-333 (1982).
156. A. K. Agarwal, N. N. Tandon, N. J. Greco, N. J. Cusack, and G. A. Jamieson, Evaluation of the binding to fixed platelets of agonists and antagonists of ADP-induced aggregation, Thromb. Haemostas., 62, 1103-1106 (1989).
157. G. Defreyn, C. Gachet, P. Savi, F. Driot, J. P. Cazenave, and J. P. Maffrand, Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adneylate cyclase in rats and rabbits, Thromb. Haemostas., 65, 186-190 (1991).
158. D. C. B. Mills, R. Puri, C.-J. Hu, C. Minniti, G. Grana, M. D. Freedman, R. F. Colman, and R. W. Colman, Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase, Arterioscler. Thrombos., 12, 430-436 (1992).
159. Y. Kawahara, J. Yamanishi, M. Tsunemitsu, and H. Fukuzaki, Protein phosphorylation and diglyceride production during serotonin release induced by epinephrine plus ADP in human platelets, Thromb. Res., 30, 477-485 (1983).
160. D. J. Carty, D. L. Freas, and A. R. L. Gear, ADP causes subsecond changes in protein phosphorylation of platelets, Blood, 70, 511-515 (1987).
161. J E. Ferrell and G. S. Martin, Tyrosine-specific protein phosphorylation is regulated by glycoprotein lib-IIIa in platelets, J. Biol. Chem. 86, 2234-2238 (1989).
162. FAK in platelets, J. Cell. Biol., 119, 905-912 (1992).
163. A. Golden, J. S. Brugge, and S J. Shattil, Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins, J. Cel. Biol., 111, 3117-3127 (1990).
164. src with triton X-100-insoluble residue in human blood platelets requires platelet aggregation and actin polymerization, J. Biol Chem., 267, 20075-20081 (1992).
165. FAK, J. Cell Biol., 122, 473-483 (1993).
166. C. Bachelot, E. Cano, F. Grelac, S. Saleun, B. J. Druker, S. Levy-Toledano, S. Fischer, and F. Rendu, Functional implications of tyrosine protein phosphorylation in platelets. Simultaneous studies with different agonists and inhibitors, Biochem. J., 284, 923-928 (1992)
167. M. Kocher and K. J. Clemetson, Staurosporine both activates and inhibits serine/threonine kinases in human platelets, Biochem. J., 275, 301-306 (1991).
168. L. K. Jennings, J. E. B. Fox, H. H. Edwards, and D. R. Phillips, Changes in the cytoskeletal structure of human platelets following thrombin activation, J. Biol. Chem., 256, 6927-6932 (1981).
169. U. Lindberg and F. Markey, "Platelet microfilaments and motility," in Platelets in Biology and Pathology III, D E. Maclntyre and J. L. Gordon, Eds., Elsevier, Amsterdam, 1987, pp. 205-237.
170. A. Oda, J. F. Daley, C. Cabrai, J. Kang, M. Smith, and E. W. Salzman, Heterogeneity in filamentous actin content among individual human blood platelets, Blood, 79, 920-927 (1992).
171. S. Heptinstall, J. Glenn, and P. Spangenberg, Changes in G-actin after platelet activation in platelet rich plasma, Thrombas. Haemostas., 68, 727-730 (1992).
172. J. F. Casella, M. D. Flanagan, and S. Lin, Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change, Nature (Lond.), 293, 302-305 (1981).
173. J. R. Glenn, S. Heptinstall, J. A. May, H. M. Sanderson, P. Spangenberg, E. Unitt, and R. G. Wilcox, Ticlopidine does not inhibit actin polymerization in ADP-induced human platelets but encourages subsequent depolymerization, Thromb. Haemostas . 69, 637, post 340 (1993).
174. J. R. McLean, R. E. Maxwell, and D. Hertler, Fibrinogen and adenosine diphosphate-induced aggregation in platelets, Nature (Lond.), 202, 605-606 (1964).
175. R. L. Nachman and L. L. K. Leung, Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen, J Clin. Invest , 69, 263-269 (1982).
176. D. R. Phillips, I. F. Charo, and R. M. Scarborough, Gp IIb-IIIa: The responsive integrin, Cell, 65, 359-362 (1991).
177. A. T. Nurden and J. P. Caen, An abnoemal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia, Br. J. Haemathol., 28, 253-260 (1974).
178. G. A. Marguerie, E. F. Plow, and T. S Edgington, Human platelets possess an inducible and saturable receptor specific for fibrinogen, J Biol. Chem., 254, 5357-5363 (1979)
179. E. J. Harfenist, M. A. Packham, and J. F. Mustard, Reversibility of the association of fibrinogen with rabbit platelets exposed to ADP, Blood, 56, 189-198 (1980).
180. J. A. Zabiocki, M. Miyano, R. B Garland, D. Pireh, L. Schretzman, S. N. Rao, R. L. Lindmark, S G. Panzer-Knodle, N. S. Nicholson, B. B. Taite, A. K. Salyers, L. W. King, J. G. Campion, and L. P Feigen, Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet Gp IIb-IIIa receptor, J. Med. Chem., 36, 1811-1819 (1993).
181. G. D. Hartman, M. S. Egbertson, W. Halczenko, W. L. Laswell, M. E. Duggan, R. L. Smith, A. M. Naylor, P. D. Manno, R. L. Lynch, G. Zhang, C. T. C. Chang, and R. L. Gould, Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors, J. Med. Chem., 35, 4640-4642 (1992).
182. A. G. Alig, A. Edenhofer, P. Hadvary, M. Hurzeler, D. Knopp, M. Müller, B. Steiner, A. Trzeciak, and T. Waller, Low molecular weight, non-peptide fibrinogen receptor antagonists, J. Med. Chem., 35, 4393-4407 (1992).
183. T. W. Ku, F. E. Ali, L. S. Barton, J. W. Bean, W. E. Bondinell, J. L. Burgess, J. F. Callahan, R. R. Calvo, L. Chen, D. S. Eggleston, J. G. Gleason, W. F. Huffman, S. M. Hwang, D. R. Jakas, C. B. Karash, R. M. Keenan, K. D. Kopple, W. H. Miller, K. A. Newlander, A. Nichols, M. F. Parker, C. E. Peishoff, J. M. Samanen, I. Uzinskas, and J. W. Venslavsky, Direct design of potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide, J. Am Chem. Soc., 115, 8861-8862 (1993).
184. S. P. Jackson, Y. Yuan, S. M Schoenwaelder, and C. A. Mitchell, Role of the platelet integrin glycoprotein IIb-IIIa in intracellular signalling, Thrombos. Res., 71, 159-168 (1993).
185. M. E. Rybak and L. A. Renzulli, Effect of calcium channel blockers on platelet Gp IIb-IIIa as a calcium channel in liposomes: Comparison with effects on the intact platelet, Thromb Haemostas., 67, 131-136 (1992).
186. J. Conard, C. Lecrubier, P. Y. Scarabin, M. H. Horellou, M. Samama, and M. G. Bousser, Effects of long term administration of ticiopidine on platelet function and hemostatic variables, Thromb. Res., 20, 143-148 (1980).
187. E. Mazoyer, L. Ripoll, M. R. Boisseau, and L. Drouet, How does ticlopidine treatment lower plasma fibrinogen?, Thromb. Res., 75(3), 361-370 (1994).
188. S. Watson, A. Abbott, Receptor nomenclature, Trends Pharmacol. Sci., Suppl. Jan, 25 (1991).
189. T. E. Webb, J. Simon, B. J. Krishek, A. N. Bateson, T. G. Smart, B. F. King, G. Burnstock, and E. A. Barnard, Cloning and functional expression of a brain G-protein-coupled ATP receptor, FEBS Lett., 324, 219-225 (1993).
190. K. D. Lustig, A. K. Shiau, A. J. Brake, and D. Julius, Expression cloning of an ATP receptor from mouse neuroblastoma cells, Proc. Natl. Acad. Sci. USA, 90, 5113-5117 (1993).
191. W. Moller and R. Amons, Phosphate-binding sequences in nucleotide-binding proteins, FEBS Lett., 186, 1-7 (1985).
192. M. Sarraste, P. R. Sibbald, and A. Wittinghofer, The P-loop - a common motif in ATP- and GTP-binding proteins, Trends Biochem. Sci., 15, 430-434 (1990).
193. M. Williams and N. J. Cusack, Neuromodulatory roles of purine nucleosides and nucleotides: Their receptors and ligands, Neurotransmissions, 4, 1-6 (1990).
194. S. A. Kalambakas, F. M. Robertson, S. M. O'Connell, S Sinha, K. Vishnupad, and G. I. Karp, Adenosine diphosphate stimulation of cultured hematopoietic cell lines, Blood, 81, 2652-2657 (1993).
195. 3H]-2-MeS-ADP on megakaryocytoblestic cell lines in culture, Biochem. Pharmacol., 48(1), 83-86 (1994).
196. 2T (adenosine diphosphate) purineigic receptors, J. Pharm. Exp. Ther., 261, 580-585 (1992).
197. P. Savi, M. C. Laplace, J P. Maffrand, J. M Herbert. Binding of [3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J. Pharm. Exp. Ther , 269, 772-777 (1994).
198. J. S. Bennett, G. Vilaire, R. F. Colman, and R. W. Colman, Localization of human platelet membrane-associated actomyosin using the affinity label 5′-p-fluorosulfonylbenzoyl adenosine, J. Biol. Chem., 256, 1185-1190 (1981).
199. R. W. Colman, Aggregin: A platelet ADP receptor that mediates activation, Faseb. J., 4, 1425-1435 (1990).
200. J. S. Bennett, R. F. Colman, and R. W. Colman, Identification of adenine nucleotide binding proteins in human platelet membranes by affinity labeling with 5′-p-fluorosulfonyl-benzoyl adenosine, J Biol. Chem., 253, 7346-7354 (1978).
201. W. R Figures, L. M. Scearce, Y. Wachtfogel, J. Chen, R. F. Colman, and R. W. Colman, Platelet ADP receptor and a2-adrenoreceptor interaction. Evidence for an ADP requirement for epinephrine-induced platelet activation and an influence of epinephrine on ADP binding, J. Biol. Chem., 261, 5981-5986 (1986).
202. D. C. B. Mills, W. R. Figures, L. M. Scearce, G. J. Stewart, R. F. Colman, and R. W. Colman, Two mechanisms for inhibition of ADP-induced platelet shape change by 5′-p-fluorosulfonylbenzoyladenosine. Conversion to adenosine, and covalent modification at an ADP binding site distinct from that which inhibits adenylate cyclase, J. Biol. Chem., 260, 8078-8083 (1985).
203. J. R. Jefferson, J. T. Harmon, and G. A. Jamieson, ADP-binding sites in platelets: Characterization by photoaffinity labeling and binding studies with fixed platelets, Thromb. Haemostas., 58, p. 451 (post 1664) (1987).
204. J. R. Adler and R. I. Handin, Solubilization and characterization of a platelet membrane ADP-binding protein, J. Biol. Chem , 254, 3866-3872 (1979).
205. N. J. Greco, N. Yamamoto, B. W. Jackson, N. N. Tandon, M. J. R. Moos, and G. A. Jamieson, Identification of a nucleotide-binding site on glycoprotein lib. Relationship to ADP-induced platelet activation, J. Biol. Chem., 266, 13627-13633 (1991).
206. M. Cattaneo, A. Lecchi, A M. Randi, J. L. McGregor, and P. M. Mannucci, Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate, Blood, 80, 2787-2796 (1992).
207. P. Nurden, P. Savi, E. Heilmann, C. Bihour, J. M. Herbert, J. P. Maffrand, and A. Nurden, An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets Its influence on GpIIb-IIIa complex function, J. Clin. Invest., 95, 1612-1622 (1995).